Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems

BMC Gastroenterology

Table 2 Score overview

	NAFLD Activity Score (NAS) (no NASH – definite NASH)					Steatosis, Activity, Fibrosis Score (SAF) (no NAFLD – NASH)					Fibrosis (no fibrosis – Stage 3 fibrosis)
	Cut-off	AUROC	SENS %	SPEC %	p-value	Cut-off	AUROC	SENS %	SPEC %	p-value	Cut-off	AUROC	SENS %	SPEC %	p-value
NCS	4	0.86	78	75	< 0.0001	5	0.77	62	72	< 0,0001	6	0.85	75	91	0.0002
LiMAx	263	0.88	80	83	< 0.0001	296	0.87	79	82	< 0.0001	292	0.53	55	58	0.72
APRI	0.08	0.76	74	67	< 0.0001	0.08	0.67	63	65	0.02	0.1	0.81	83	76	< 0.0001
Fib-4	0.67	0.58	53	54	0.25	0.71	0.57	51	54	0.36	0.78	0.67	49	65	0.02
NFS	−0.47	0.63	63	61	0.07	−1.02	0.62	59	58	0.09	−0.44	0.68	55	62	0.11

Abbreviations: NAS NAFLD Activity Score, SAF Steatosis, Activity, Fibrosis Score, NASH NASH: non-alcoholic steatohepatitis, NAFLD non-alcoholic fatty liver disease, AUROC Area under the Receiver Operating Characteristic, SENS Sensitivity, SPEC Specificity, NCS NASH Clinical Scoring System, LiMAx LiMAx liver function capacity test, APRI aspartate aminotransferase to platelet ratio index, NFS NAFLD fibrosis score

ISSN: 1471-230X